Literature DB >> 11574101

Association of APOE epsilon4 allele with survival in amyotrophic lateral sclerosis.

V E Drory1, M Birnbaum, A D Korczyn, J Chapman.   

Abstract

APOE epsilon4 allele is associated with poorer outcome in degenerative neurological diseases. Its role in amyotrophic lateral sclerosis (ALS) is still unclear. The aim of the present study was to further analyze the association of APOE epsilon4 allele with progression and survival of ALS. One hundred consecutive ALS patients (53 males) and 133 controls were genotyped for the APOE epsilon4 allele. The association of this allele with survival to death or tracheostomy was analyzed by Kaplan-Meier survival analysis. The frequency of the APOE epsilon4 allele in ALS patients was slightly higher (15.1%) than in the control group (10.9%). Patients with or without an APOE epsilon4 allele had a similar age of onset and frequency of bulbar onset. There was a significant shortening of the 50% probability of survival (by 32 months) in patients carrying the APOE epsilon4 allele (p=0.03). In conclusion, carrying an APOE epsilon4 allele is a poor prognostic factor in ALS. This is compatible with a role of apolipoprotein on neuronal survival and repair.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574101     DOI: 10.1016/s0022-510x(01)00569-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  28 in total

Review 1.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

Review 2.  Complex genetics of amyotrophic lateral sclerosis.

Authors:  Catherine B Kunst
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

3.  Crystallization and preliminary X-ray diffraction analysis of apolipoprotein E-containing lipoprotein particles.

Authors:  Yvonne Newhouse; Clare Peters-Libeu; Karl H Weisgraber
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-10-20

4.  The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80.

Authors:  Selam Negash; Pamela M Greenwood; Trey Sunderland; Raja Parasuraman; Yonas E Geda; David S Knopman; Bradley F Boeve; Robert J Ivnik; Ronald C Petersen; Glenn E Smith
Journal:  Neuropsychology       Date:  2009-01       Impact factor: 3.295

Review 5.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

6.  Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis.

Authors:  Kathryn C Fitzgerald; Éilis J O'Reilly; Guido J Falcone; Marjorie L McCullough; Yikyung Park; Laurence N Kolonel; Alberto Ascherio
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

Review 7.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

8.  Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis.

Authors:  Yi-Ju Li; Margaret A Pericak-Vance; Jonathan L Haines; Nailah Siddique; Diane McKenna-Yasek; Wu-Yen Hung; Peter Sapp; Coy I Allen; Wenjie Chen; Betsy Hosler; Ann M Saunders; Lisa M Dellefave; Robert H Brown; Teepu Siddique
Journal:  Neurogenetics       Date:  2004-10-02       Impact factor: 2.660

Review 9.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 10.  Targeting angiogenin in therapy of amyotropic lateral sclerosis.

Authors:  Hiroko Kishikawa; David Wu; Guo-fu Hu
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.